Melinta Therapeutics, Inc. Common Stock
MLNT
MLNT was delisted on the 10th of January, 2020.
37 hedge funds and large institutions have $584K invested in Melinta Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 17 closing their positions.
542% more call options, than puts
Call options by funds: $289K | Put options by funds: $45K
21% less funds holding
Funds holding: 47 → 37 (-10)
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
59% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 17
94% less capital invested
Capital invested by funds: $9.43M → $584K (-$8.85M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$102K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$98.9K |
| 3 |
CCM
Condor Capital Management
Martinsville,
New Jersey
|
+$70.3K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$68.8K |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$58.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$2.22M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.69M |
| 3 |
SC
Sculptor Capital
New York
|
-$374K |
| 4 |
BlackRock
New York
|
-$360K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$268K |
MLNT Hedge Fund Activity: Q4 2019 in Review
37 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Melinta Therapeutics, Inc. Common Stock (MLNT) for Q4 2019, worth a combined $584K — down 94% from $9.43M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of MLNT and 7 opened new positions — a net loss of 10 holders — while 12 trimmed existing stakes and 7 added.
The largest buyer was Citadel Advisors, adding an estimated $102K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $2.22M sold.
- 37 institutional investors held Melinta Therapeutics, Inc. Common Stock (MLNT) as of Q4 2019, down from 47 in Q3 2019.
- Funds reported $584K of Melinta Therapeutics, Inc. Common Stock stock for Q4 2019, down 94% quarter-over-quarter.
- 7 funds opened new Melinta Therapeutics, Inc. Common Stock positions in Q4 2019 and 17 closed out, a net change of -10 holders.
- The largest Melinta Therapeutics, Inc. Common Stock buyer in Q4 2019 was Citadel Advisors, an estimated $102K added.
- The largest Melinta Therapeutics, Inc. Common Stock seller in Q4 2019 was Renaissance Technologies, an estimated $2.22M sold.
Based on aggregated 13F filings for Q4 2019.